Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Kurowski

Showing results (61-70 of 73) with videos related to

Pageof 8
Sort By:
Antiviral Therapy|January 6, 2001
Phenotypic HIV-1 resistance correlates with treatment outcome of nelfinavir salvage therapyH Walter, B Schmidt, A Rascu, et al.
The Journal of Antimicrobial Chemotherapy|September 25, 2009
Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patientsM Bickel, A Bodtländer, G K Knecht, et al.
The American Journal of Tropical Medicine and Hygiene|July 19, 2021
Social and Environmental Determinants of Community-Acquired Antimicrobial-Resistant Escherichia coli in Children Living in Semirural Communities of Quito, EcuadorKathleen M Kurowski, Rachel Marusinec, Heather K Amato, et al.
Antimicrobial Resistance and Infection Control|January 7, 2021
Caretaker knowledge, attitudes, and practices (KAP) and carriage of extended-spectrum beta-lactamase-producing E. coli (ESBL-EC) in children in Quito, EcuadorRachel Marusinec, Kathleen M Kurowski, Heather K Amato, et al.
Allergy|June 10, 2017
Mechanisms of exercise-induced bronchoconstriction in athletes: Current perspectives and future challengesM Couto, M Kurowski, A Moreira, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1996
A phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancerN J Meropol, Y M Rustum, N J Petrelli, et al.
European Journal of Medical Research|September 3, 2002
Predictors of treatment failure during highly active antiretroviral therapy (racing trial)A Masuhr, M Mueller, V Simon, et al.
Allergy|June 24, 2015
Pathophysiological mechanisms of exercise-induced anaphylaxis: an EAACI position statementL Ansley, M Bonini, L Delgado, et al.
BMJ Global Health|June 19, 2026
Vaccination coverage and timeliness among children in EthiopiaClara Pons-Duran, Bezawit Mesfin Hunegnaw, Chalachew Bekele, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 6, 2010
Therapy failure following selection of enfuvirtide-resistant HIV-1 in cerebrospinal fluidS F L van Lelyveld, M Nijhuis, F Baatz, et al.
Pageof 8

Showing results (61-70 of 73) with videos related to

Sort By:
Pageof 8
Antiviral Therapy|January 6, 2001
Phenotypic HIV-1 resistance correlates with treatment outcome of nelfinavir salvage therapyH Walter, B Schmidt, A Rascu, et al.
The Journal of Antimicrobial Chemotherapy|September 25, 2009
Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patientsM Bickel, A Bodtländer, G K Knecht, et al.
The American Journal of Tropical Medicine and Hygiene|July 19, 2021
Social and Environmental Determinants of Community-Acquired Antimicrobial-Resistant Escherichia coli in Children Living in Semirural Communities of Quito, EcuadorKathleen M Kurowski, Rachel Marusinec, Heather K Amato, et al.
Antimicrobial Resistance and Infection Control|January 7, 2021
Caretaker knowledge, attitudes, and practices (KAP) and carriage of extended-spectrum beta-lactamase-producing E. coli (ESBL-EC) in children in Quito, EcuadorRachel Marusinec, Kathleen M Kurowski, Heather K Amato, et al.
Allergy|June 10, 2017
Mechanisms of exercise-induced bronchoconstriction in athletes: Current perspectives and future challengesM Couto, M Kurowski, A Moreira, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1996
A phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancerN J Meropol, Y M Rustum, N J Petrelli, et al.
European Journal of Medical Research|September 3, 2002
Predictors of treatment failure during highly active antiretroviral therapy (racing trial)A Masuhr, M Mueller, V Simon, et al.
Allergy|June 24, 2015
Pathophysiological mechanisms of exercise-induced anaphylaxis: an EAACI position statementL Ansley, M Bonini, L Delgado, et al.
BMJ Global Health|June 19, 2026
Vaccination coverage and timeliness among children in EthiopiaClara Pons-Duran, Bezawit Mesfin Hunegnaw, Chalachew Bekele, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 6, 2010
Therapy failure following selection of enfuvirtide-resistant HIV-1 in cerebrospinal fluidS F L van Lelyveld, M Nijhuis, F Baatz, et al.
Pageof 8